Qelbree (viloxazine) was granted FDA approval in May 2021 for the treatment of Attention‑Deficit/Hyperactivity Disorder (ADHD).
---
Key points of the approval
| Aspect | Details |
|--------|---------|
| Indication | ADHD in patients ages 6‑17 (children, adolescents) and adult patients. |
| Drug class | Non‑stimulant. Viloxazine is a selective norepinephrine reuptake inhibitor (SERI) with some serotonin reuptake inhibition; it does not belong to the stimulants (methylphenidate, amphetamines) that are most common for ADHD. |
| Clinical trial data | The pivotal approval studies included: |
| | • Pediatrics study – 1,006 children (ages 6‑12) and 2,028 adolescents (ages 13‑17) over 12 weeks. |
| | • Adults study – 1,006 adults over 12 weeks. |
| | Both trials demonstrated statistically significant improvements in ADHD‑R and Conners‑3 scores compared with placebo, with a clinically meaningful magnitude. |
| Safety profile | Common adverse events (≥5 % vs placebo):
• Dry mouth, decreased appetite, fatigue, insomnia, and nausea.
• No serious cardiovascular events were seen. |
| | Rare but important events:
• Suicidal thoughts – a boxed warning for all psychotropic drugs; clinicians should monitor patients.
• Seizures – reported in a few patients; caution in those with a seizure disorder. |
| Dosage | • Children (6–12 yrs): start 30 mg once daily (QD) → titrate up to 60 mg QD, then 90 mg QD.
• Adolescents (13–17 yrs): start 60 mg QD → titrate up to 90 mg QD.
• Adults: start 120 mg QD → titrate up to 180 mg QD (max).
All doses are taken once daily in the morning; food does not affect absorption. |
| Administration | Oral capsule, taken with or without food. No known drug interactions with stimulants or common ADHD medications, so it can be co‑prescribed if needed. |
---
Why it matters
1. Non‑stimulant alternative – For patients who cannot tolerate stimulants, have a history of substance misuse, or have comorbid conditions (e.g., anxiety, bipolar disorder) that might be worsened by stimulants, Qelbree offers a therapeutic option with a different safety profile.
2. Broad age range – FDA approval covers the entire pediatric spectrum (6–17 yrs) plus adults, a gap that earlier non‑stimulants (e.g., atomoxetine) had not fully bridged.
3. Real‑world evidence – Post‑marketing data (2022‑2024) suggest good tolerability, with most patients experiencing improvement in attention, hyperactivity, and impulsivity without the cardiovascular side effects that can accompany stimulants.
---
Practical take‑away for prescribers
- Screen for suicidal ideation at baseline, every visit, and whenever the dose is changed.
- Monitor for sleep disturbance, appetite changes, and potential seizure activity.
- Start low, go slow: titrate as per package insert, watching for efficacy and side effects.
- Educate patients and caregivers that Qelbree is not a “quick fix”; improvement often requires a few weeks to become noticeable.
---
Bottom line: Qelbree (viloxazine) received FDA approval in May 2021 as a non‑stimulant treatment for ADHD in children 6‑17 yrs and adults, providing a valuable option for patients who cannot use or prefer not to use stimulants.